rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Greenwich LifeSciences, Inc.

GLSI · Nasdaq

Health CareBiotechnologyNot moving yet

GLSI stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 16 weeks. It is 20.0% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 16
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$972K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
58 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$348KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months13
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Snehal PatelCEO and CFObought700at $13.1029 Jul 2026filed 30 Jul 2026
Snehal PatelCEO and CFObought1,500at $13.5928 Jul 2026filed 30 Jul 2026
Snehal PatelCEO and CFObought1,500at $13.6227 Jul 2026filed 29 Jul 2026
Snehal PatelCEO and CFObought1,100at $12.8824 Jul 2026filed 27 Jul 2026
Snehal PatelCEO and CFObought2,500at $13.1423 Jul 2026filed 27 Jul 2026
Snehal PatelCEO and CFObought1,800at $29.8313 Jan 2026filed 15 Jan 2026
Snehal PatelCEO and CFObought2,900at $27.5412 Jan 2026filed 14 Jan 2026
Snehal PatelCEO and CFObought4,300at $21.3631 Dec 2025filed 5 Jan 2026
Snehal PatelCEO and CFObought2,900at $21.7330 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders58-4 on the quarter
New · exited9 · 13
Reported value$39.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 2026485,854$11.4M+51,994+12.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026278,190$6.5M-20,076−6.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026168,179$3.9M+12,713+8.2%
STATE STREET CORPadded · filed 7 Aug 2026143,086$3.4M+9,211+6.9%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 202680,861$1.9M+21,950+37.3%
NORTHERN TRUST CORPadded · filed 13 Aug 202680,228$1.9M+5,103+6.8%
Bank of New York Mellon Corpadded · filed 6 Aug 202647,900$1.1M+1,377+3.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202645,965$1.1M+1,057+2.4%
MORGAN STANLEYadded · filed 13 Aug 202643,447$1.0M+13,620+45.7%
GOLDMAN SACHS GROUP INCreduced · filed 14 Aug 202639,329$923K-192−0.5%
31 Mar 2023 – 30 Jun 2026
224160Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Snehal Patel Company insiderCEO and CFO · last 29 Jul 202686 · 0
David McWilliams Company insiderDirector · last 24 Dec 20243 · 0
Eric Rothe Company insiderDirector · last 24 Dec 20241 · 0
Frank Joseph Daugherty Company insiderChief Medical Officer · last 24 Dec 20245 · 0
Jaye Thompson Company insiderVP Clinical Reg Affairs · last 24 Dec 202421 · 0
Kenneth Hallock Company insiderDirector · last 24 Dec 20245 · 0
Pankaj Amrit Patel Company insider10% owner · last 10 Nov 20200 · 0
Kinnary Patel Company insider10% owner · last 29 Sep 20200 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 26 May 20262.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.2M

Analyst forecasts

No analyst forecasts yet.